{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:06:39Z","timestamp":1751623599735},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1991,10,1]],"date-time":"1991-10-01T00:00:00Z","timestamp":686275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmacokinetics and Biopharmaceutics"],"published-print":{"date-parts":[[1991,10]]},"DOI":"10.1007\/bf01062964","type":"journal-article","created":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T02:16:45Z","timestamp":1107224205000},"page":"575-595","source":"Crossref","is-referenced-by-count":21,"title":["Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose"],"prefix":"10.1007","volume":"19","author":[{"given":"J.","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wanwimolrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. D.","family":"Purves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. G.","family":"McQueen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[1991,10,1]]},"reference":[{"key":"BF01062964_CR1","doi-asserted-by":"crossref","first-page":"285S","DOI":"10.1111\/j.1365-2125.1980.tb01811.x","volume":"10","author":"G. Levy","year":"1981","unstructured":"G. Levy. Clinical pharmacokinetics of salicylates: An assessment.Br. J. Clin. Pharmacol. 10:285S-290S (1981).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BF01062964_CR2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1056\/NEJM197208312870903","volume":"287","author":"G. Levy","year":"1972","unstructured":"G. Levy and T. Tsuchiya. Salicylate accumulation kinetics in man.New Engl. J. Med. 287:430\u2013432 (1972).","journal-title":"New Engl. J. Med."},{"key":"BF01062964_CR3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cpt1978236635","volume":"23","author":"J. T. Wilson","year":"1978","unstructured":"J. T. Wilson, R. L. Howell, M. W. Holladay, G. M. Brulis, J. Chraslil, J. T. Watson, and D. F. Taber. Gentisuric acid: Metabolic formation in animols and identification as a metabolite of aspirin in man.Clin. Pharmacol. Ther. 23:635\u2013643 (1978).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF01062964_CR4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jps.2600540703","volume":"54","author":"G. Levy","year":"1965","unstructured":"G. Levy. Pharmacokinetics of salicylate elimination in man.J. Pharm. Sci. 54:959\u2013967 (1965).","journal-title":"J. Pharm. Sci."},{"key":"BF01062964_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/03602537909046431","volume":"9","author":"G. Levy","year":"1979","unstructured":"G. Levy. Pharmacokinetics of salicylate in man.Drug Metab. Rev. 9:3\u201319 (1979).","journal-title":"Drug Metab. Rev."},{"key":"BF01062964_CR6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cpt1972132258","volume":"13","author":"G. Levy","year":"1972","unstructured":"G. Levy, T. Tsuchiya, and L. P. Amsel. Limited capacity of salicyl phenolic glucuronide formation and its effects on the kinetics of salicylate elimination in man.Clin. Pharmacol. Ther. 13:258\u2013268 (1972).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF01062964_CR7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00543800","volume":"25","author":"M. S. Roberts","year":"1983","unstructured":"M. S. Roberts, R. H. Rumble, S. Wanwimolruk, D. Thomas, and P. M. Brooks. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease.Eur. J. Clin. Pharmacol 25:253\u2013261 (1983).","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"BF01062964_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jps.2600610409","volume":"61","author":"T. Tsuchiya","year":"1972","unstructured":"T. Tsuchiya and G. Levy. Relationship between dose and plateau levels of drugs eliminated by parallel first order and capacity-limited kinetics.J. Pharm. Sci. 61:541\u2013544 (1972).","journal-title":"J. Pharm. Sci."},{"key":"BF01062964_CR9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/jps.2600610530","volume":"61","author":"T. Tsuchiya","year":"1972","unstructured":"T. Tsuchiya and G. Levy. Biotransformation of salicylic acid and its acyl and phenolic glucuronides in man.J. Pharm. Sci. 61:800\u2013801 (1972).","journal-title":"J. Pharm. Sci."},{"key":"BF01062964_CR10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1476-5381.1969.tb09546.x","volume":"37","author":"D. R. Boreham","year":"1969","unstructured":"D. R. Boreham and B. K. Martin. The kinetics of elimination of salicylic acid and formation of gentisic acid.Br. J. Pharmacol. 37:294\u2013297 (1969).","journal-title":"Br. J. Pharmacol."},{"key":"BF01062964_CR11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/cpt1979263380","volume":"26","author":"D. E. Furst","year":"1979","unstructured":"D. E. Furst, T. N. Tozer, and K. L. Melmon. Salicylate clearance, the resultant of protein binding and metabolism.Clin. Pharmacol. Ther. 26:380\u2013389 (1979).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF01062964_CR12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/clpt.1984.81","volume":"35","author":"M. Gunsberg","year":"1984","unstructured":"M. Gunsberg, F. Bochner, G. Graham, D. Imhoff, G. Parsons, and B. Cham. Disposition of and clinical response to salicylates in patients with rheumatoid disease.Clin. Pharmacol. Ther. 35:585\u2013593 (1984).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF01062964_CR13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/cpt1976204464","volume":"20","author":"O. Borga","year":"1976","unstructured":"O. Borga, I. Odear-Cederlof, V-A. Ringberger, and A. Norlin. Protein binding of salicylate in uremic and normal plasma.Clin. Pharmacol. Ther. 20:464\u2013475 (1976).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF01062964_CR14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-197904020-00006","volume":"4","author":"R. Ekstrand","year":"1979","unstructured":"R. Ekstrand, G. Alvan, and O. Borga. Concentration dependent plasma protein binding of salicylate in rheumatoid patients.Clin. Pharmacokin. 4:137\u2013143 (1979).","journal-title":"Clin. Pharmacokin."},{"key":"BF01062964_CR15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00561662","volume":"9","author":"W. D. Wosilait","year":"1976","unstructured":"W. D. Wosilait. Theoretical analysis of the binding of salicylate by human serum albumin: The relationship between free and bound drug and therapeutic levels.Eur. J. Clin. Pharmacol. 9:285\u2013290 (1976).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF01062964_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.2042-7158.1983.tb04282.x","volume":"35","author":"G. Rubin","year":"1983","unstructured":"G. Rubin, T. N. Tozer, and S. \u00d8ie. Concentration-dependence of salicylate distribution.J. Pharm. Pharmacol. 35:115\u201317 (1983).","journal-title":"J. Pharm. Pharmacol."},{"key":"BF01062964_CR17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1172\/JCI103667","volume":"37","author":"D. Schachter","year":"1958","unstructured":"D. Schachter and J. G. Manis. Salicylate and solicyl conjugates: Fluorimetric estimation, biosynthesis and renal excretion in man.J. Clin. Invest. 37:800\u2013807 (1958).","journal-title":"J. Clin. Invest."},{"key":"BF01062964_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0014-5793(81)80173-1","volume":"129","author":"L. Zimmerman","year":"1981","unstructured":"L. Zimmerman, H. Jorhvall, J. Bergstrom, P. Furst, and J. Sjovall. Characterization of a double conjugate in uremic body fluids.FEBS Letters 129:237\u2013240 (1981).","journal-title":"FEBS Letters"},{"key":"BF01062964_CR19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0378-4347(91)80392-P","volume":"565","author":"J. Shen","year":"1991","unstructured":"J. Shen, S. Wanwimolruk, and M. S. Roberts. A novel direct high-performance liquid Chromatographic (HPLC) method for determination of salicylate glucuronide metabolites in human urine.J. Chromatog. Biomed. Appl. 565:309\u2013320 (1991).","journal-title":"J. Chromatog. Biomed. Appl."},{"key":"BF01062964_CR20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2125.1989.tb03526.x","volume":"28","author":"S. G. Owen","year":"1989","unstructured":"S. G. Owen, M. S. Roberts, W. T. Friesen, and H. W. Francis. Salicylate pharmacokinetics in patients with rheumatoid arthritis.Br. J. Clin. Pharmacol. 28:449\u2013461 (1989).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BF01062964_CR21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/01483919008051818","volume":"13","author":"J. Shen","year":"1990","unstructured":"J. Shen, S. Wanwimolruk, C. R. Clark, and M. S. Roberts. A sensitive assay for aspirin and its metabolites using reversed-phase ion-pair high-performance liquid chromatography.J. Liquid Chromatog. 13:751\u2013761 (1990).","journal-title":"J. Liquid Chromatog."},{"key":"BF01062964_CR22","unstructured":"M. Rowland and T. N. Tozer.Clinical Pharmacokinetics, 2nd ed., Lea & Febiger, (1989)."},{"key":"BF01062964_CR23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01061505","volume":"2","author":"A. J. Sedman","year":"1974","unstructured":"A. J. Sedman and J. G. Wagner. Quantitative pooling of Michaelis-Menten equations in models with parallel metabolite formation paths.J. Pharmacokin. Biopharm. 2:149\u2013161 (1974).","journal-title":"J. Pharmacokin. Biopharm."},{"key":"BF01062964_CR24","first-page":"R665","volume":"246","author":"E. M. Landaw","year":"1984","unstructured":"E. M. Landaw and J. J. DiStefano. Multiexponential, multicompartmental and noncompartmental modeling. II. Data analysis and statistical considerations.Am. J. Physiol. 246:R665-R677 (1984).","journal-title":"Am. J. Physiol."},{"key":"BF01062964_CR25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/clpt.1981.158","volume":"30","author":"F. Bochner","year":"1981","unstructured":"F. Bochner, G. G. Graham, B. E. Cham, D. M. Imhoff, and T. M. Haavisto. Salicylate metabolite kinetics after several salicylates.Clin. Pharmacol. Ther. 30:266\u2013275 (1981).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF01062964_CR26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-198308030-00005","volume":"8","author":"D. O. Day","year":"1983","unstructured":"D. O. Day, D. D. Shen, and D. L. Azarnoff. Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates.Clin. Pharmacokin. 8:263\u2013271 (1983).","journal-title":"Clin. Pharmacokin."},{"key":"BF01062964_CR27","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jps.2600570807","volume":"57","author":"M. Rowland","year":"1968","unstructured":"M. Rowland and S. Riegelman. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man.J. Pharm. Sci. 57:1313\u20131319 (1968).","journal-title":"J. Pharm. Sci."},{"key":"BF01062964_CR28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jps.2600590319","volume":"59","author":"M. Rowland","year":"1970","unstructured":"M. Rowland, L. J. Benet, and S. Riegelman. Two-compartment model for a drug and its metabolite: Application to acetylsalicylic acid pharmacokinetics.J. Pharm. Sci. 59:364\u2013367 (1970).","journal-title":"J. Pharm. Sci."},{"key":"BF01062964_CR29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00542188","volume":"32","author":"F. Bochner","year":"1987","unstructured":"F. Bochner, G. G. Graham, A. Polverino, D. M. Imhofi, R. A. Tregenza, P. E. Rolan, and L. G. Cleland. Solicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.Eur. J. Clin. Pharmacol. 32:153\u2013158 (1987).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BF01062964_CR30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1172\/JCI108766","volume":"60","author":"D. E. Furst","year":"1977","unstructured":"D. E. Furst, N. Gupta, and H. E. Paulus, Salicylate metabolism in twins: Evidence suggesting a genetic influence and induction of salicylurate formation.J. Clin. Invest. 60:32\u201342 (1977).","journal-title":"J. Clin. Invest."}],"container-title":["Journal of Pharmacokinetics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01062964.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01062964\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01062964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T23:09:16Z","timestamp":1556579356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01062964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1991,10]]}},"alternative-id":["BF01062964"],"URL":"https:\/\/doi.org\/10.1007\/bf01062964","relation":{},"ISSN":["0090-466X"],"issn-type":[{"value":"0090-466X","type":"print"}],"subject":[],"published":{"date-parts":[[1991,10]]}}}